#Deep dive
Long-form pieces over 2,000 words.
GIP Agonists and Blockers in Obesity
A 2026 review asks why GIP receptor agonists and blockers can both support weight loss, then separates mouse mechanisms from human trial evidence.
Semaglutide and Podocyte Senescence
Semaglutide cuts kidney disease events in trials. Researchers now ask whether slowing podocyte senescence in kidney filter cells explains part of why.
MASH fibrosis treatment panel update
An expert panel maps how semaglutide and resmetirom may fit MASH care, while long-term outcomes and direct comparisons remain open.
Semaglutide and MASH: what ESSENCE found
Semaglutide has a licensed indication for MASH, the inflamed form of fatty liver disease. Here is what the ESSENCE trial showed, and what it has not.
GLP-1 and GIP: a short incretin history
Incretins went from a failed 1906 diabetes experiment to GLP-1 and GIP drugs. Here are the dates, the discoveries, and where the evidence thins out.
Tirzepatide history: discovery to approval
Six milestones trace how tirzepatide went from a laboratory dual-agonist hypothesis in 2018 to one of the most-studied prescription medicines in the world.
Tesamorelin: from discovery to FDA approval
How tesamorelin moved from a lab compound to FDA approval in 2010, and why the European application was withdrawn in 2012.
A short history of TB-500
TB-500 (thymosin beta-4) was first sequenced in 1981. Four decades on, it has no approved human use and only one controlled trial, in eye disease.
Semax: from 1991 lab bench to today
Semax is licensed in Russia for stroke recovery but unapproved in the West. Here is how it got from a Moscow lab in 1991 to today's grey market.
Ipamorelin history: discovery to today
Ipamorelin was first characterised at Novo Nordisk in 1998. Here is the research timeline and why no approved medicine followed.